EPS for Abeona Therapeutics Inc. (ABEO) Expected At $-0.23

November 10, 2018 - By olga

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.23 EPS on November, 21.They anticipate $0.10 EPS change or 76.92 % from last quarter’s $-0.13 EPS. After having $-0.25 EPS previously, Abeona Therapeutics Inc.’s analysts see -8.00 % EPS growth. The stock decreased 5.26% or $0.52 during the last trading session, reaching $9.36. About 591,945 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 5.07% since November 11, 2017 and is uptrending. It has underperformed by 10.55% the S&P500.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 5 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 8 analyst reports since May 14, 2018 according to SRatingsIntel. The company was initiated on Tuesday, June 5 by Seaport Global. The firm has “Buy” rating given on Tuesday, June 5 by H.C. Wainwright. The firm earned “Buy” rating on Monday, May 21 by Cantor Fitzgerald. Cantor Fitzgerald maintained it with “Buy” rating and $3600 target in Tuesday, May 15 report. H.C. Wainwright maintained the shares of ABEO in report on Monday, May 14 with “Buy” rating. The company was maintained on Tuesday, May 29 by H.C. Wainwright. Jefferies maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, May 22 with “Buy” rating.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $448.75 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Streetinsider.com which released: “Regenxbio (RGNX), Abeona (ABEO) Announce Worldwide Exclusive Licenses for Treatment of Four Rare Lysosomal …” on November 05, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on October 12, 2018, Seekingalpha.com published: “Abeona Therapeutics: A Potential Leader In Gene Therapy” on November 01, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: Schaeffersresearch.com and their article: “2 Drug Stocks Popping on Fresh “Buy” Ratings” published on October 12, 2018 as well as Globenewswire.com‘s news article titled: “Investor Expectations to Drive Momentum within Cincinnati Bell, Hooker Furniture, AgroFresh Solutions, Forward …” with publication date: October 16, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>